Articles

Marvell and Astera Labs can continue growing alongside Nvidia, according to Jefferies.

Howard Marks said he believes it will take a good amount of time before AI technologies start impacting non-AI companies.

Chicago Fed President Austan Goolsbee said Monday there are new signs of stress on the economy that should make the U.S. central bank at least wonder if its policy rate needs to be as high as it currently is.

The case comes as scholarships tied to race and ethnicity are posing challenges to donors and schools in the wake of the Supreme Court’s affirmative action decision

Alnylam Pharmaceuticals’ stock jumped nearly 40% premarket on Monday after the company released results of a late-stage trial for a heart drug that analysts see competing with a key Pfizer treatment.

Analyst Keith Horowitz said Ally Financial offers “the best way” to play an economic recovery within Citi’s coverage universe due to “fixed rate asset repricing potential combined with a liability sensitive balance sheet.”

An analyst thinks Wall Street still underestimates AI’s potential to drive iPhone device upgrades.

In a 35-page report, Muddy Waters said Eurofins Chief Executive Gilles Martin has spent decades enriching himself through improper real-estate deals

The move is the latest in a wave of M&A offerings aimed at Vista, a maker of outdoor products and ammunition, for all or parts of its business.

Packaging giant Sonoco is poised to become the leading metal-food-can maker globally.

Tom Lee, who accurately predicted the 2023 rally, lays out a path for the S&P 500 to triple in the next few years.

California-based biopharmaceutical company plans to trade on the Nasdaq under the symbol ALMS.